Video: High Sensitivity TSO500 Detection

Discovery Life Sciences developed a bundled NGS solution using Illumina's TruSight Oncology 500 that delivers actionable, reliable sequencing data across matched FFPE tumor and cell-free DNA plasma biospecimens. This integrated approach enables researchers to advance biomarker programs by generating comprehensive genomic insights from both solid tumors and circulating DNA in a single workflow.
Scientist.com
公開日
November 10, 2020

On November 10, 2020, Discovery Life Sciences’ Dr. Shawn Levy — Chief Scientific Officer of Discovery Life Sciences’ sequencing and bioinformatics laboratory, HudsonAlpha Discovery — presented about some of their latest technologies.

He explained how Discovery Life Sciences has developed a new bundled solution leveraging Illumina’s TruSight Oncology 500 (TSO00) Solid Tumor (FFPE) and cfDNA that delivers actionable, reliable NGS data across matched FFPE tumor and plasma biospecimens and discussed how their services could be used to advance biomarker programs.

You can access the entire presentation recording below, including a very informative Q&A session.

If you have questions for Discovery Life Sciences, email them at genomics@dls.com or access their profile page on Scientist.com .

Interested in hosting a webinar with Scientist.com? Contact us at marketing@scientist.com .

Abstract molecular cluster with three connected blue-green spheres on a white background.

次のステップへ進む

1
2
3

Explore Suppliers

関連する専門知識を持つ信頼できるパートナーを探す

Review Capabilities

サービス、経験、実績を比較する

Start Your Project

つながり、協業を始める

執筆者
Scientist.com
この記事をシェアする

続きを読む

続きを読む